Doris Tate
Nurse Practitioner · Easton, MDNPI 1275975542
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $30,701 of the $34,314 with a category attached, or 89.5%. Insulet Corporation accounts for 90.6% of it on its own, with 20 other manufacturers making up the rest. Reporting peaked in 2023 at $16,311 and has fallen 97.6% since, to $390 in 2025. Among nurse practitioner clinicians in MD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 163 payments — averaging $210.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Insulet Corporation$31K
- Sanofi-aventis U.S. LLC$693
- Novo Nordisk$577
- Dexcom, Inc.$566
- AstraZeneca$296
- Tandem Diabetes Care, Inc.$185
- plus $916 from 15 others
What the payments were for
- Speaking & faculty fees$30,70189%
- Travel & lodging$2431%
- Food & beverage$3,28710%
- Education$830%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Insulet Corporation | 55 | $31,080 |
| Sanofi-aventis U.S. LLC | 16 | $693 |
| Novo Nordisk | 28 | $577 |
| Dexcom, Inc. | 13 | $566 |
| AstraZeneca | 15 | $296 |
| Tandem Diabetes Care, Inc. | 3 | $185 |
| Lilly USA, LLC | 8 | $174 |
| Galderma Laboratories, L.p. | 2 | $141 |
| Corcept Therapeutics | 3 | $126 |
| Revance Therapeutics, Inc. | 5 | $109 |
| Merz North America, Inc. | 1 | $94 |
| Boehringer Ingelheim | 3 | $54 |
| Bayer | 1 | $39 |
| Lifescan, Inc. | 2 | $39 |
| Merck | 2 | $36 |
| BETA Bionics, Inc. | 1 | $22 |
| Zealand Pharma US, Inc. | 1 | $20 |
| Xeris Pharmaceuticals, Inc. | 1 | $20 |
| Cequr Corporation | 1 | $17 |
| Medtronic | 1 | $13 |
| Intuity Medical Inc | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Omnipod$30,411
- DEXCOM G7 GSS (161)$111
- DEXCOM STELO GLUCOSE BIOSENSOR$111
- Ozempic$111
- SOLIQUA 100/33$102
How this compares
$34,314 in reported general payments places this provider in the 95th percentile of 1,562 nurse practitioner providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 342 | $398,170 |
| OzempicSemaglutide | 245 | $391,392 |
| JardianceEmpagliflozin | 219 | $216,886 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 113 | $164,137 |
| TrulicityDulaglutide | 92 | $139,694 |
| FarxigaDapagliflozin Propanediol | 82 | $100,393 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 78 | $71,571 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 52 | $68,206 |
| JanuviaSitagliptin Phosphate | 67 | $60,924 |
| FiaspInsulin Aspart (Niacinamide) | 49 | $55,844 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 40 | $47,763 |
| TradjentaLinagliptin | 34 | $46,908 |
| Tresiba Flextouch U-100Insulin Degludec | 59 | $38,124 |
| RybelsusSemaglutide | 12 | $30,910 |
| Tresiba Flextouch U-200Insulin Degludec | 29 | $25,465 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Lyumjev, Humalog, Insulin Lispro | $174 | $562,212494 claims |
| Novo NordiskOzempic, Fiasp, Rybelsus, Novolog | $577 | $489,825356 claims |
| Boehringer IngelheimJardiance, Tradjenta | $54 | $263,793253 claims |
| AstraZenecaFarxiga | $296 | $100,39382 claims |
| MerckJanuvia | $36 | $60,92467 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $693 | $47,76340 claims |
| Cequr CorporationCequr Simplicity | $17 | $6,89616 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,562 nurse practitioner providers in Maryland.
Other nurse practitioner in Easton
- Margaret WilliamsEaston$9K
- Morgan GaleRockville$292K
- Sherilyn BrinkleyBaltimore$100K
- Michelle TurnerBaltimore$94K
- Nelli ZafmanLutherville$67K
- Ellen LancasterFallston$52K
- Zeev NemirovskyBaltimore$19K
- Martha ReilleyAnnapolis$18K
- Stephanie ZwonitzerAnnapolis$16K
- Jennifer MaglianoTimonium$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.